Skip to main content
. 2019 Apr 11;59(9):1188–1194. doi: 10.1002/jcph.1414

Figure 1.

Figure 1

Mean ± SD upadacitinib plasma concentration‐versus‐time profiles (log and log‐linear scales) in subjects with normal hepatic function and those with mild or moderate hepatic impairment. Sensitivity analysis excluding the subject with moderate hepatic impairment who had distinctively low upadacitinib exposure. The upadacitinib plasma concentration value for the 120‐hour time was below the assay limit of quantification across all subjects and all groups.